These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 17575164)

  • 1. Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis.
    Struyf S; Burdick MD; Peeters E; Van den Broeck K; Dillen C; Proost P; Van Damme J; Strieter RM
    Cancer Res; 2007 Jun; 67(12):5940-8. PubMed ID: 17575164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The COOH-terminal peptide of platelet factor-4 variant (CXCL4L1/PF-4var47-70) strongly inhibits angiogenesis and suppresses B16 melanoma growth in vivo.
    Vandercappellen J; Liekens S; Bronckaers A; Noppen S; Ronsse I; Dillen C; Belleri M; Mitola S; Proost P; Presta M; Struyf S; Van Damme J
    Mol Cancer Res; 2010 Mar; 8(3):322-34. PubMed ID: 20215425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stimulation of angiostatic platelet factor-4 variant (CXCL4L1/PF-4var) versus inhibition of angiogenic granulocyte chemotactic protein-2 (CXCL6/GCP-2) in normal and tumoral mesenchymal cells.
    Vandercappellen J; Noppen S; Verbeke H; Put W; Conings R; Gouwy M; Schutyser E; Proost P; Sciot R; Geboes K; Opdenakker G; Van Damme J; Struyf S
    J Leukoc Biol; 2007 Dec; 82(6):1519-30. PubMed ID: 17827342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of angiostatic platelet factor-4var/CXCL4L1 counterbalances angiogenic impulses of vascular endothelial growth factor, interleukin-8/CXCL8, and stromal cell-derived factor 1/CXCL12 in esophageal and colorectal cancer.
    Verbeke H; De Hertogh G; Li S; Vandercappellen J; Noppen S; Schutyser E; El-Asrar AA; Opdenakker G; Van Damme J; Geboes K; Struyf S
    Hum Pathol; 2010 Jul; 41(7):990-1001. PubMed ID: 20334899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer.
    Vandercappellen J; Van Damme J; Struyf S
    Cytokine Growth Factor Rev; 2011 Feb; 22(1):1-18. PubMed ID: 21111666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCL4L1 and CXCL4 signaling in human lymphatic and microvascular endothelial cells and activated lymphocytes: involvement of mitogen-activated protein (MAP) kinases, Src and p70S6 kinase.
    Van Raemdonck K; Gouwy M; Lepers SA; Van Damme J; Struyf S
    Angiogenesis; 2014 Jul; 17(3):631-40. PubMed ID: 24469069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Chemokine Platelet Factor-4 Variant (PF-4var)/CXCL4L1 Inhibits Diabetes-Induced Blood-Retinal Barrier Breakdown.
    Abu El-Asrar AM; Mohammad G; Nawaz MI; Abdelsaid M; Siddiquei MM; Alam K; Van den Eynde K; De Hertogh G; Opdenakker G; Al-Shabrawey M; Van Damme J; Struyf S
    Invest Ophthalmol Vis Sci; 2015 Feb; 56(3):1956-64. PubMed ID: 25711636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis.
    Struyf S; Burdick MD; Proost P; Van Damme J; Strieter RM
    Circ Res; 2004 Oct; 95(9):855-7. PubMed ID: 15459074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3.
    Struyf S; Salogni L; Burdick MD; Vandercappellen J; Gouwy M; Noppen S; Proost P; Opdenakker G; Parmentier M; Gerard C; Sozzani S; Strieter RM; Van Damme J
    Blood; 2011 Jan; 117(2):480-8. PubMed ID: 20980681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CXCL4L1 inhibits angiogenesis and induces undirected endothelial cell migration without affecting endothelial cell proliferation and monocyte recruitment.
    Sarabi A; Kramp BK; Drechsler M; Hackeng TM; Soehnlein O; Weber C; Koenen RR; Von Hundelshausen P
    J Thromb Haemost; 2011 Jan; 9(1):209-19. PubMed ID: 20961394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of the Mig (CXCL9) gene in murine lung carcinoma cells generated angiogenesis-independent antitumor effects.
    Wang YQ; Wada A; Ugai S; Tagawa M
    Oncol Rep; 2003; 10(4):909-13. PubMed ID: 12792744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autocrine CCL2, CXCL4, CXCL9 and CXCL10 signal in retinal endothelial cells and are enhanced in diabetic retinopathy.
    Nawaz MI; Van Raemdonck K; Mohammad G; Kangave D; Van Damme J; Abu El-Asrar AM; Struyf S
    Exp Eye Res; 2013 Apr; 109():67-76. PubMed ID: 23352833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CXCL4L1-fibstatin cooperation inhibits tumor angiogenesis, lymphangiogenesis and metastasis.
    Prats AC; Van den Berghe L; Rayssac A; Ainaoui N; Morfoisse F; Pujol F; Legonidec S; Bikfalvi A; Prats H; Pyronnet S; Garmy-Susini B
    Microvasc Res; 2013 Sep; 89():25-33. PubMed ID: 23747987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PF-4var/CXCL4L1 predicts outcome in stable coronary artery disease patients with preserved left ventricular function.
    De Sutter J; Van de Veire NR; Struyf S; Philippé J; De Buyzere M; Van Damme J
    PLoS One; 2012; 7(2):e31343. PubMed ID: 22384011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiostatic, tumor inflammatory and anti-tumor effects of CXCL4(47-70) and CXCL4L1(47-70) in an EGF-dependent breast cancer model.
    Van Raemdonck K; Berghmans N; Vanheule V; Bugatti A; Proost P; Opdenakker G; Presta M; Van Damme J; Struyf S
    Oncotarget; 2014 Nov; 5(21):10916-33. PubMed ID: 25373734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of plasma chemokines in cancer].
    Struyf S; Van Damme J
    Verh K Acad Geneeskd Belg; 2007; 69(3):149-65. PubMed ID: 17580816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet factor 4 gene transfection into tumor cells inhibits angiogenesis, tumor growth and metastasis.
    Yamaguchi K; Ogawa K; Katsube T; Shimao K; Konno S; Shimakawa T; Yoshimatsu K; Naritaka Y; Yagawa H; Hirose K
    Anticancer Res; 2005; 25(2A):847-51. PubMed ID: 15868918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet factor-4 (CXCL4/PF-4): an angiostatic chemokine for cancer therapy.
    Wang Z; Huang H
    Cancer Lett; 2013 May; 331(2):147-53. PubMed ID: 23337289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis.
    Addison CL; Arenberg DA; Morris SB; Xue YY; Burdick MD; Mulligan MS; Iannettoni MD; Strieter RM
    Hum Gene Ther; 2000 Jan; 11(2):247-61. PubMed ID: 10680839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity.
    Maione TE; Gray GS; Hunt AJ; Sharpe RJ
    Cancer Res; 1991 Apr; 51(8):2077-83. PubMed ID: 1706960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.